Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Livermore

Showing results (291-300 of 807) with videos related to

Pageof 81
Sort By:
The Journal of Antimicrobial Chemotherapy|December 28, 2018
Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing EnterobacteriaceaeShazad Mushtaq, Anna Vickers, Neil Woodford, et al.
The Journal of Antimicrobial Chemotherapy|March 27, 2001
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and WalesA P Johnson, M Warner, R C George, et al.
The Journal of Antimicrobial Chemotherapy|June 6, 2007
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypesShazad Mushtaq, Marina Warner, Yigong Ge, et al.
The Journal of Antimicrobial Chemotherapy|October 10, 2008
Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06David M Livermore, Russell Hope, Geraldine Brick, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2007
Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC methodR Hope, T Parsons, S Mushtaq, et al.
Journal of Chemotherapy (Florence, Italy)|March 28, 2014
Prevalence and antimicrobial resistance among Gram-negative pathogens in Saudi ArabiaSaber Yezli, Atef M Shibl, David M Livermore, et al.
The Journal of Antimicrobial Chemotherapy|November 5, 2020
Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemasesShazad Mushtaq, Danièle Meunier, Anna Vickers, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2020
Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its "Sell-By Date" in an Era of New Antibiotics and Regional Carbapenemase EpidemiologyDavid M Livermore, David P Nicolau, Katie L Hopkins, et al.
The New England Journal of Medicine|November 27, 1986
Randomized trial of allopurinol in the prevention of calcium oxalate calculiB Ettinger, A Tang, J T Citron, et al.
The Journal of Antimicrobial Chemotherapy|August 16, 2022
Activity of ertapenem/zidebactam (WCK 6777) against problem EnterobacteralesShazad Mushtaq, Paolo Garello, Anna Vickers, et al.
Pageof 81

Showing results (291-300 of 807) with videos related to

Sort By:
Pageof 81
The Journal of Antimicrobial Chemotherapy|December 28, 2018
Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing EnterobacteriaceaeShazad Mushtaq, Anna Vickers, Neil Woodford, et al.
The Journal of Antimicrobial Chemotherapy|March 27, 2001
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and WalesA P Johnson, M Warner, R C George, et al.
The Journal of Antimicrobial Chemotherapy|June 6, 2007
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypesShazad Mushtaq, Marina Warner, Yigong Ge, et al.
The Journal of Antimicrobial Chemotherapy|October 10, 2008
Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06David M Livermore, Russell Hope, Geraldine Brick, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2007
Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC methodR Hope, T Parsons, S Mushtaq, et al.
Journal of Chemotherapy (Florence, Italy)|March 28, 2014
Prevalence and antimicrobial resistance among Gram-negative pathogens in Saudi ArabiaSaber Yezli, Atef M Shibl, David M Livermore, et al.
The Journal of Antimicrobial Chemotherapy|November 5, 2020
Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemasesShazad Mushtaq, Danièle Meunier, Anna Vickers, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2020
Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its "Sell-By Date" in an Era of New Antibiotics and Regional Carbapenemase EpidemiologyDavid M Livermore, David P Nicolau, Katie L Hopkins, et al.
The New England Journal of Medicine|November 27, 1986
Randomized trial of allopurinol in the prevention of calcium oxalate calculiB Ettinger, A Tang, J T Citron, et al.
The Journal of Antimicrobial Chemotherapy|August 16, 2022
Activity of ertapenem/zidebactam (WCK 6777) against problem EnterobacteralesShazad Mushtaq, Paolo Garello, Anna Vickers, et al.
Pageof 81